Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details)

v3.21.2
Basis of Presentation and Significant Accounting Policies (Details)
1 Months Ended 3 Months Ended 9 Months Ended 64 Months Ended
Dec. 11, 2020
Jan. 07, 2020
USD ($)
Nov. 01, 2017
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2017
USD ($)
May 31, 2017
USD ($)
Jun. 30, 2016
USD ($)
May 31, 2016
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
segment
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Basis of Presentation and Significant Accounting Policies                                  
Reverse stock split conversion ratio 0.1429                                
Accumulated deficit                 $ 152,155,580   $ 152,155,580   $ 152,155,580 $ 130,647,485      
Net loss                 7,548,225 $ 8,916,433 21,791,941 $ 19,826,671          
Cash, cash equivalents and short term investments                 108,900,000   108,900,000   108,900,000        
Derivative warrant liability                 30,971   $ 30,971   $ 30,971 $ 33,779      
Number of operating segments | segment                     1            
Goodwill                                  
Goodwill, Impairment Loss                     $ 0            
Deferred Revenue                                  
Deferred revenue grant received from economic development grant     $ 200,000                            
Minimum time period to meet certain employment levels     7 years                            
Revenue Recognition                                  
Revenue                 501,567 849,732 1,499,706 2,344,777          
Allowable expenses incurred under NIH grant                 $ 0.0   $ 30,000.00            
Pelican Therapeutics, Inc.                                  
Basis of Presentation and Significant Accounting Policies                                  
Ownership interest in subsidiary                 85.00%   85.00%   85.00% 85.00% 85.00% 80.00%  
Pelican Therapeutics, Inc.                                  
Basis of Presentation and Significant Accounting Policies                                  
Percentage of voting interests acquired in acquisition                                 80.00%
Grant revenue | Maximum                                  
Revenue Recognition                                  
Amount awarded from NIH grant   $ 224,713                              
Grant revenue | Pelican Therapeutics, Inc.                                  
Revenue Recognition                                  
Amount awarded from CPRIT grant               $ 15,200,000                  
Revenue                   $ 0   $ 0 $ 14,600,000        
Remaining grant amount receivable                 $ 1,500,000   $ 1,500,000   $ 1,500,000        
Grant revenue | Pelican Therapeutics, Inc. | Maximum                                  
Revenue Recognition                                  
Amount awarded from CPRIT grant             $ 15,200,000                    
Grant revenue | Tranche 1 | Pelican Therapeutics, Inc.                                  
Revenue Recognition                                  
Revenue           $ 1,800,000                      
Grant revenue | Tranche 2 | Pelican Therapeutics, Inc.                                  
Revenue Recognition                                  
Revenue         $ 6,500,000                        
Grant revenue | Tranche 3 | Pelican Therapeutics, Inc.                                  
Revenue Recognition                                  
Revenue       $ 5,400,000